This HTML5 document contains 42 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n14http://linked.opendata.cz/resource/drugbank/company/
n15http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n12http://linked.opendata.cz/resource/drugbank/drug/DB01398/identifier/wikipedia/
n11http://linked.opendata.cz/resource/drugbank/drug/DB01398/identifier/pharmgkb/
n7http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n13http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n10http://linked.opendata.cz/resource/drugbank/drug/DB01398/identifier/kegg-drug/
n9http://linked.opendata.cz/resource/drugbank/drug/DB01398/identifier/drugbank/

Statements

Subject Item
n2:DB01398
rdf:type
n3:Drug
n3:description
Sodium salicylate is a sodium salt of salicylic acid. It can be prepared from sodium phenolate and carbon dioxide under higher temperature and pressure. It is used in medicine as an analgesic and antipyretic. Sodium salicylate also acts as non-steroidal anti-inflammatory drug (NSAID) and induces apoptosis in cancer cells. It is also potential replacement for aspirin for people sensitive to it.
n3:group
approved
n3:indication
It is used in medicine as an analgesic and antipyretic. Sodium salicylate also acts as non-steroidal anti-inflammatory drug (NSAID)
owl:sameAs
n7:DB01398 n15:DB01398
dcterms:title
Salicylate-sodium
adms:identifier
n9:DB01398 n10:D00566 n11:PA451428 n12:Sodium_salicylate
n3:mechanismOfAction
Salicylate-sodium is considered a non-selective COX inhibitor—that is, it inhibits two isoforms of cyclooxygenase, COX-1 and COX-2. The analgesic, antipyretic, and anti-inflammatory activity of NSAIDs appears to be achieved mainly through inhibition of COX-2, whereas inhibition of COX-1 would be responsible for unwanted effects on platelet aggregation and the gastrointestinal tract. However, the role of the individual COX isoforms in the analgesic, anti-inflammatory, and gastric damage effects of NSAIDs is uncertain and different compounds cause different degrees of analgesia and gastric damage. Salicylate-sodium directly and irreversibly inhibits the activity of both types of cyclo-oxygenases (COX-1 and COX-2) to decrease the formation of precursors of prostaglandins and thromboxanes from arachidonic acid. Salicylate may competitively inhibit prostaglandin formation. Salicylate's antirheumatic (nonsteroidal anti-inflammatory) actions are a result of its analgesic and anti-inflammatory mechanisms.
n3:packager
n14:271B45DF-363D-11E5-9242-09173F13E4C5
n3:synonym
Salsonin
n3:IUPAC-Name
n4:271B45E5-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B45EB-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B45EA-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B45E7-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B45E8-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B45E9-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B45E3-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B45E1-363D-11E5-9242-09173F13E4C5 n4:271B45E4-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B45E2-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B45F1-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B45F2-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B45EC-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B45ED-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B45EF-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B45EE-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B45F0-363D-11E5-9242-09173F13E4C5
n3:category
n3:containedIn
n13:271B45E0-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B45F7-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B45F9-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B45FA-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B45F6-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B45F5-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B45F8-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B45E6-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B45F3-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B45F4-363D-11E5-9242-09173F13E4C5